Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an oral, direct-acting, reversible P2Y12 platelet inhibitor. It is used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Primary Indications
* **Acute Coronary Syndrome (ACS):** Prevention of thrombotic cardiovascular events in patients with ACS, including unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI).
* **History of Myocardial Infarction (MI):** In patients with a history of MI, ticagrelor is indicated to reduce the rate of thrombotic cardiovascular events in combination with aspirin.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months, or longer if clinically indicated and tolerated. Some patients may benefit from continuing ticagrelor beyond 12 months.
* **History of MI (at least 1 year post-MI):**
* **Maintenance Dose:** 60 mg orally twice daily. This dose should be used in patients who have had an MI at least 1 year prior and are already taking aspirin and at least one other antiplatelet agent.
## Pediatric Dosing
Ticagrelor is not approved for use in pediatric patients.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is recommended for mild to moderate hepatic impairment. Ticagrelor is not recommended in severe hepatic impairment.
* **Renal Impairment:** No dose adjustment is required for mild, moderate, or severe renal impairment.
## Contraindications
* Active bleeding.
* Known history of intracranial hemorrhage.
* Hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Common:** Dyspnea, bleeding (e.g., bruising, epistaxis, gastrointestinal bleeding, genitourinary bleeding), bradycardia, ventricular pauses.
* **Serious:** Major bleeding, life-threatening bleeding, symptomatic bradycardia requiring intervention, thrombotic thrombocytopenic purpura (TTP) (rare).
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin) may increase ticagrelor exposure. Avoid strong CYP3A4 inhibitors.
* **CYP3A4 Inducers:** Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) may decrease ticagrelor exposure and efficacy.
* **P-glycoprotein (P-gp) Substrates:** Ticagrelor can inhibit P-gp. Consider potential for increased exposure of P-gp substrates (e.g., digoxin).
* **Aspirin:** When used with aspirin, ticagrelor has been shown to increase the risk of bleeding, but also to be more effective in preventing ischemic events than clopidogrel plus aspirin in ACS.
* **Other Anticoagulants/Antiplatelets:** Increased risk of bleeding.
* **NSAIDS:** Increased risk of bleeding.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding.
* **Cardiac Rhythm:** Monitor for symptomatic bradycardia, especially in patients with risk factors.
* **Renal and Hepatic Function:** Baseline and periodic monitoring as clinically indicated.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, meaning its effect can be reversed more quickly upon discontinuation compared to clopidogrel.
* The 90 mg twice-daily dose is typically used for ACS. The 60 mg twice-daily dose is reserved for patients at least 1 year post-MI.
* Dyspnea is a common side effect and is usually mild and transient, but patients should be evaluated for underlying causes.
* Discontinuation of ticagrelor should be avoided if possible, as it increases the risk of stent thrombosis, MI, and death, particularly within the first few months of treatment.
* Ticagrelor should be taken for the duration recommended by the physician, even if bleeding occurs, unless the bleeding is life-threatening.
---
*This information is intended for healthcare professionals. Always consult the official prescribing information and your institution's guidelines for the most current and complete drug information.*
